Who makes CAR.B7-H3T cells infusion?

CAR.B7-H3T cells infusion is developed by UNC Lineberger Comprehensive Cancer Center.

What development phase is CAR.B7-H3T cells infusion in?

CAR.B7-H3T cells infusion is in Phase 1.

Last reviewed 2026-04-20 · How we verify

CAR.B7-H3T cells infusion

UNC Lineberger Comprehensive Cancer Center · Phase 1 active Small molecule Quality 3/100

At a glance

Generic name	CAR.B7-H3T cells infusion
Sponsor	UNC Lineberger Comprehensive Cancer Center
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CAR.B7-H3T cells infusion CI brief — competitive landscape report
CAR.B7-H3T cells infusion updates RSS · CI watch RSS
UNC Lineberger Comprehensive Cancer Center portfolio CI